RPA
IHE icon

Rock Point Advisors’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Rock Point Advisors’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,633
Closed -$225K – 109
2023
Q4 		$225K Buy
+3,633
New +$214K 0.07% 95

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
AWM
Accurate Wealth Management Wesley Chapel, Florida $1.05B AUM 30.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
VCM
Virtue Capital Management Brentwood, Tennessee $749M AUM 40.13% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CIC
Concord Investment Counsel Irvine, California $366M AUM 38.82% 1-Year Est. Return

Rock Point Advisors's IHE Position: Q1 2024 in Review

Rock Point Advisors sold out of iShares US Pharmaceuticals ETF (IHE) in Q1 2024, closing a stake of 3,633 shares — an estimated $225K sold.

Rock Point Advisors first reported a position in IHE in Q4 2023 and held it in 1 quarter. The position peaked at $225K in Q4 2023. 143 funds tracked by Wall St. Rank hold IHE as of Q1 2024.

  • Rock Point Advisors reported no remaining iShares US Pharmaceuticals ETF position as of Q1 2024 after selling out during the quarter.
  • Rock Point Advisors sold 3,633 iShares US Pharmaceuticals ETF shares in Q1 2024, an estimated $225K.
  • Rock Point Advisors first reported a position in iShares US Pharmaceuticals ETF in Q4 2023 and held it in 1 quarter.
  • Rock Point Advisors's iShares US Pharmaceuticals ETF position peaked at $225K in Q4 2023.
  • 143 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2024.

Based on Rock Point Advisors's 13F filing for Q1 2024, filed 10 May 2024.